Financial Performance - Q3 2025 revenue was $41.6 million[32] - Nucleic Acid Products (NAP) revenue was $25.4 million[15, 33] - Biologics Safety Testing (BST) revenue was $16.3 million[14, 33] - GAAP Net Loss was $45.1 million[38] - Adjusted EBITDA was a loss of $10.8 million[38] - Basic and Diluted EPS were both losses of $0.18, while Adjusted EPS was a loss of $0.08[40] - Cash used in operations was $15.2 million[44] Guidance and Future Outlook - The company expects to lower annualized expenses by more than $50 million[17] - The company anticipates sequential Adjusted EBITDA improvements in Q4 of more than $7 million[17] - The company expects annual revenue contribution from COVID GMP CleanCap® to be $10 million to $20 million starting in 2026[23] - 2025 revenue is expected to be approximately $185 million, and Adjusted EBITDA is expected to be a loss of approximately $35 million[51]